|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income (loss) | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Provision for credit losses | |||||
| Depreciation on premises and equipment | |||||
| Impairment on goodwill | |||||
| Amortization of intangible assets | |||||
| Amortization of operating lease right-of-use asset | |||||
| Amortization of loan servicing rights | |||||
| Share-based compensation expense | |||||
| Increase in cash surrender value of life insurance | |||||
| Gain on proceeds from company-owned life insurance | |||||
| Investment securities accretion, net | |||||
| Gain on termination of hedged interest rate swaps | |||||
| (Gain) loss on sales of investment securities, net | |||||
| Gain on repurchase of subordinated debt | |||||
| Gain on sales of other real estate owned | |||||
| Impairment on other real estate owned | |||||
| Origination of loans held for sale | |||||
| Proceeds from sales of loans and leases held for sale | |||||
| Gain on sale of loans held for sale | |||||
| Impairment on commercial mortgage servicing rights | |||||
| Loss on mortgage servicing rights held for sale | |||||
| Loss on sale of loan portfolios | |||||
| Impairment on leased assets and surrendered assets | |||||
| Net change in operating assets and liabilities: | |||||
| Accrued interest receivable | |||||
| Credit enhancement asset | |||||
| Other assets | |||||
| Accrued expenses and other liabilities | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of investment securities available for sale | |||||
| Proceeds from sales of investment securities available for sale | |||||
| Maturities and payments on investment securities available for sale | |||||
| Purchases of equity securities | |||||
| Proceeds from sales of equity securities | |||||
| Net decrease in loans | |||||
| Proceeds from sales of consumer loans held for sale | |||||
| Proceeds from sales of loan portfolios | |||||
| Purchases of premises and equipment | |||||
| Proceeds from sale of premises and equipment | |||||
| Purchases of nonmarketable equity securities | |||||
| Proceeds from redemptions of nonmarketable equity securities | |||||
| Proceeds from sales of other real estate owned | |||||
| Proceeds from company-owned life insurance, net | |||||
| Net cash acquired in acquisitions | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash flows from financing activities: | |||||
| Net decrease in deposits | |||||
| Net increase (decrease) in short-term borrowings | |||||
| Net increase (decrease) in short-term FHLB advances | |||||
| Proceeds from long-term FHLB advances | |||||
| Payments made on long-term FHLB advances and other borrowings | |||||
| FHLB advances prepayment fees | |||||
| Payments and subordinated debt redemption | |||||
| Proceeds from issuance of preferred stock | |||||
| Cash dividends paid on preferred stock | |||||
| Cash dividends paid on common stock | |||||
| Common stock repurchased | |||||
| Proceeds from issuance of common stock under employee benefit plans | |||||
| Net cash used in financing activities | |||||
| Net increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents: | |||||
| Beginning of period | |||||
| End of period | |||||
Loading...
